Phaseline

Targets › APOA

APOA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Cardiovascular; next expected readout Mar 2031.

Open in Phaseline: the race on APOA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyMuvalaplin (LY3473329)
Lipoprotein(a) biosynthesis inhibitor
APOAPhase 3Elevated Lp(a)Mar 2031

Conditions

Elevated Lp(a) (1)

Modalities

small molecule (1)

Companies

Eli Lilly (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.